



Radium Ra 223 Dichloride

Revised: October 15, 2023.

CASRN: 444811-40-9

Drug Levels and Effects

Summary of Use during Lactation

Radium-223 dichloride is not indicated for use in women and should not be given to nursing mothers. However, if a nursing mother receives radium-223 dichloride, she should permanently discontinue nursing her current infant.[1]

Drug Levels

Radium-223 has a physical half-life of 11.4 days and emits alpha particles with a decay energy of 5.979 MeV upon decay.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

References

1. Dilsizian V, Metter D, Palestro C, Zanzonico P. Advisory Committee on Medical Uses of Isotopes (ACMUI) Sub-Committee on Nursing Mother Guidelines for the Medical Administration of Radioactive Material. Final report submitted: January 31, 2019. 2019. Available at: <https://www.nrc.gov/docs/ML1903/ML19038A498.pdf>

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.

Substance Identification

Substance Name

Radium Ra 223 Chloride

CAS Registry Number

444811-40-9

Drug Class

Breast Feeding

Lactation

Milk, Human

Antineoplastic Agents

Radiopharmaceuticals

Radionuclides

Radium